ZPL 5212372

Drug Profile

ZPL 5212372

Alternative Names: PF-05212372; PF-5212372; PLA-950; ZPL-521; ZPL-5212372

Latest Information Update: 14 Jun 2016

Price : $50

At a glance

  • Originator
  • Developer Pfizer; Ziarco
  • Class Antiasthmatics
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Atopic dermatitis
  • Clinical Phase Unknown Psoriasis
  • Discontinued Asthma

Most Recent Events

  • 01 Jun 2016 Phase-I/II clinical trials in Atopic dermatitis in United Kingdom (Topical) (NCT02795832)
  • 05 Feb 2016 Ziarco plans a phase I/IIa trial for Psoriasis in the second quarter of 2016 (Ziarco website, July 2015)
  • 05 Feb 2016 Ziarco plans a clinical trial for Atopic dermatitis in mid-2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top